Fda grants permission to enroll up to 8 additional secondary progressive multiple sclerosis (spms) patients in the expanded access program with intranasal foralumab

New york, april 05, 2022 (globe newswire) -- tiziana life sciences (nasdaq:  tlsa ) ("tiziana" or the "company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of monoclonal antibody delivery, today announced that its collaborators at the brigham and women's hospital (bwh) boston ma have received a ‘study may proceed letter' from the u.s. food and drug administration (fda) permitting initiation of treatment in up to an additional eight spms patients as part of an intermediate-size patient population expanded access ind.
TLSA Ratings Summary
TLSA Quant Ranking